<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Immuno-oncology Targets & Combinations

Leverage comprehensive in vitro, in vivo, ex vivo, and in silico platforms, utilizing immunocompetent, humanized, or patient-derived models. With robust biomarker analysis and a focus on checkpoint inhibitors, you can optimize combination strategies.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development

Tumor Infiltrating Immune CellsTumor-Infiltrating Immune Cells: Explore how the identification and quantification of tumor-infiltrating lymphocytes (TILs) can help evaluating the efficacy of novel immunotherapy agents.

Syngeneic Tumor Models in Immuno-Oncology

Immuno-oncology (I/O) therapies elicit their activity by modulating the immune system of the host so it can identify and destroy tumor cells. There are several mechanisms through which I/O drugs can modulate the immune system, including:

  • Overcoming tumor-induced suppression mechanisms
  • Stimulating cytotoxic activity of immune cells
  • Increasing the presence of immune cells in the tumor microenvironment

Syngeneic tumor models are widely used in preclinical I/O studies because they are immune-competent and therefore have fully intact and functional immune systems. Studying novel immunotherapy agents in the context of a functional immune system is critical because these models recapitulate the complex interactions that exist between the immune system and tumors. Any alterations of the immune system components, either systemically or at the tumor site, can be monitored in these models. Additionally, studies have demonstrated that these models respond to clinically relevant immunotherapies, both in combination and as monotherapies.

A challenge often encountered with syngeneic tumor models is that they require cross-reactive therapeutics so they can recognize murine targets. However, this challenge can be overcome by using a combination of transgenic syngeneic mice (i.e. mice expressing human targets on their immune cells), syngeneic tumor models overexpressing a human antigen, or using chimeric (human/mouse) antibody-based agents.

Why Profile the Immune System?

Since I/O therapies elicit their activity by modulating the immune system, it is important to directly profile the immune system to analyze how the I/O agent(s) affect the immune system. This assessment is useful for preclinical efficacy and pharmacodynamic (PD) studies, as immune profiling can determine, or confirm, the mechanism of action (MoA) of an immunotherapy.

Specifically, immune profiling can be used to assess the following parameters/variables:

  • Inflammatory status of the tumor model, which can guide tumor model selection for efficacy/PD studies

  • Abundance of the therapeutic-relevant effector cells in the tumor model or syngeneic host, which can determine thresholds needed for efficacy/PD studies, as well as selecting appropriate study models

  • Increased infiltration of immune cells at the tumor site. This can be determined by profiling the tumor with and without treatment, which can be used to confirm the MoA

  • Activation and exhaustion status of immune cells to determine the PD effect of the therapeutic

  • Systemic inflammatory responses such as cytokine-release syndrome and cytokine storm, assessed by immune profiling and cytokine profiling of the host

  • Off-target/toxic effects, assessed by immune profiling of non-target tissues

How to Perform Immune Profiling

Immune profiling can be achieved using a variety of methods, including:

  • Flow cytometry (FC): The most commonly used method to profile tumors and other mouse tissues, including the blood. Advantages of FC include quantifying different types of immune cells and determining the activation state of immune cells, by evaluating the upregulation/downregulation of specific biomarkers, including cell surface proteins and intracellular cytokines. While FC can quantify the immune cells in a tumor/tissue, it does not provide information about the specific location of the infiltrating cells, since the tissues are homogenized for analysis. A further limitation is that the number of parameters that can be analyzed simultaneously is limited based on the equipment available. Newer cytometers with more advanced laser systems may alleviate this problem, but currently we are limited to 12-15 parameters per staining panel.

  • Mass cytometry (CyTOF): Similar to FC, antibodies are used to label cellular proteins for analysis in CyTOF. However, instead of having antibodies conjugated to fluorophores, as in FC, CyTOF relies on antibodies that are conjugated to isotopically pure heavy metals (which are normally not present in biological samples). The samples are analyzed by time-of-flight mass spectrometry. The main advantage to CyTOF is the expanded number of parameters than can be analyzed simultaneously due to the low overlap in signal detection among the isotopes, as compared to fluorophores. CyTOF can be used for quantification of immune cell types and activation markers. However, the tissue also has to be processed which results in a loss of spatial information.

  • Immunohistochemistry (IHC): This method is a semi-quantitative assay for immune profiling, where tissue sections are directly analyzed, providing spatial information of various immune cells. IHC can provide insights into the MoA/PD effect of the therapeutic, in cases where there are not significant changes in the total number of cells between treated and untreated tissues. IHC is the most cost-efficient method listed here, but it is also the method that measures the lowest number of variables at once.

  • Next generation sequencing (NGS): Generally used in combination with one of the immune profiling methods described above, NGS is helpful for developing an in-depth profile of the transcriptome and receptor repertoire of specific immune populations. Genome-wide changes of the immune system – even at the single-cell level – after treatment with immunotherapies can be interrogated using NGS strategies.

  • Multiplex Spatial Tissue Analysis (MSTA): Provides a comprehensive and spatially relevant picture of biomarker distribution within a tissue sample. MSTA has come to fruition largely due to advances in digital technologies and new analytical capabilities (e.g. photo-cleavable barcodes and spatially defined UV exposure, and laser/ion-beam ablation of metal-or isotope-labelled antibodies). MSTA can now be used to simultaneously evaluate hundreds of nucleic acid and/or protein markers in a spatially relevant context.

Conclusion

Since syngeneic tumor models have an intact and functional immune system, they are widely used in preclinical studies of novel immunotherapies. To better understand the MoA/PD of novel I/O agents, changes in the immune system components, either systemically or at the tumor-site, are often monitored in these models. Such profiling and analyses of tumor-infiltrating immune cells can provide key insights to enhance the development trajectory of novel I/O agents. The five methods for immune profiling highlighted have their own benefits and limitations which should be taken into consideration before selecting a method for any study. This will maximize the likelihood that the method selected will answer the specific research questions at hand.


Related Posts